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Sunmarv Selective internal radiation therapy (SIR therapy) is a technique whereby metastatic liver cancer is
irradiated by embolising microspheres containing the radionuclide yttrium-90 into the hepatic artenral circula-
tion. To date this technique has not been used as an adjuvant therapy. but rather to treat established
metastases in the liver. This study evaluated the use of two intrahepatic radiation doses delivered on
radioactive microspheres for the treatment of small, growing micrometastases. Three groups of five rats were
each inoculated with tumour spheroids into the portal vein. The resultant liver micrometastases were treated
with either 10 or 20 MBq of yttrium-90 microspheres or a sham dose of non-radioactive microspheres injected
into the portal vein 2 days following tumour inoculation. The livers of each animal were examined for the
presence of metastases after a further 21 days and liver function tests were performed. At the time of sacrifice
there was no obvious normal liver damage in any of the rats treated with microspheres. The livers of the
sham-treated animals contained extensive signs of tumour deposition. A mean of 34 tumours were taken from
the livers of each of the sham-treated animals, whereas only a single tumour was found in one animal treated
with 10 MBq of yttrium and eight small tumours from two animals treated with 20 MBq. Liver function tests
demonstrated a significant short-term increase in alkaline phosphatase levels in the radiation-treated animals
compared with shams, but there were no other indications of any effects on liver function. These results
indicate a potential role for SIR therapy in an adjuvant setting with colorectal cancer.
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The occurrence of liver metastases is a common development
from a number of different forms of malignancy but is
especially prevalent in patients first diagnosed with primary
colorectal cancer. Hepatic metastases are evident in approx-
imately a quarter of patients at initial diagnosis, but this is
more than doubled at the time of death (Bengmark and
Hafstrom, 1969). Approximately 70% of the metastases attri-
buted to tumours of the large bowel are fdund in the liver,
and half the deaths from bowel cancer result from disease in
the liver (Gray, 1980).
Over the past two decades there have been many random-
ised clinical trials that have assessed the potential of adjuvant
chemotherapy and radiotherapy to improve survival in
patients undergoing resection for primary tumours of the
large bowel. The past 3 years has seen a resurgence of
interest in this area as several of these trials have now
demonstrated positive results (Gray et al., 1987; Laurue et
al., 1989; Moertel et al., 1990).
Of particular interest is the fact that three of the prospec-
tively randomised trials have demonstrated an improvement
in survival with the use of regional perfusion chemotherapy
of the liver as an adjuvant treatment (Taylor et al., 1985;
Gray et al., 1987; Wolmark et al., 1990). In all three of these
clinical trials a relatively small dose of chemotherapy was
delivered directly into the portal venous circulation following
removal of the primary tumour in patients who had either
stage B or C large bowel cancer. These data indicate that
elimination or suppression of micrometastases within the
liver in patients at high risk of developing clinically obvious
recurrent cancer can translate into a survival improvement
when the chemotherapy is given directly into the portal
venous circulation.
In earlier studies we have shown that even very small
subclinical metastases derive their blood supply almost
entirely from the hepatic artery and that metastases as small
as 1 mm in diameter have a well-defined arterial blood supply
and that this arterial supply will occur in a short period of
time (Archer and Gray. 1989). Microscopic deposits smaller
than this are nourished by diffusion of nutrients from the
portal vein before they have developed their own arterial
blood supply. Therefore, it might be expected that cytotoxic
drugs delivered into the portal vein would only be effective
against micrometastases of much less than 1 mm in diameter
and that they would have little effect on larger 'micrometas-
tases.
We have shown that this is exactly what does happen in an
animal model of liver metastases. In these studies it was
shown that portal venous chemotherapy is only effective
against metastatic tumour deposits that have not had time to
develop their own arterial blood supply. Portal venous
chemotherapy had little effect on metastases as small as
1 mm in diameter, whereas the same chemotherapy delivered
via the hepatic artery was highly effective in eliminating these
tumour deposits (Archer and Gray, 1990). This effect may be
associated with the low tissue penetration of the
chemotherapy drugs, which are unable to diffuse from the
portal veins to the arterial feeding vessels of the larger
deposits.
As would be expected, many studies have established that
the objective response rate for treatment of liver metastases is
considerably higher when the chemotherapy is delivered
directly into the hepatic arterial circulation, as opposed to
systemic therapy (Daly et al., 1987; Archer and Gray, 1990).
SIR therapy is a technique developed by our group for
selectively concentrating radioactive microspheres containing
yttrium-90 into the vascular compartment of malignant
tumours within the liver (Burton and Gray, 1989; Gray et al..
1989, 1992). In patients with liver metastases derived from
the large bowel, the objective response rate of established
metastases to treatment by SIR therapy exceeds that of other
treatment techniques, including hepatic perfusion chemo-
therapy (Gray et al., 1992). The yttrium-90 used in SIR
therapy has a relatively long penetration distance relative to
chemotherapeutic drugs and may provide therapeutic levels
of radiation from portal veins to hepatic arteries. Therefore.
there is obvious potential to use SIR therapy as an adjuvant
treatment for patients undergoing resection of pnrmary
tumours of the large bowel but who are at high risk of
developing liver metastases.
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September 1994The current study was designed to evaluate the potential of
using a relatively small and a high intrhepatic radiation
dose delivered on radioactive microspheres via the portal vein
to retard the growth of micrometastases in an animal model
of liver metastasis.
MateriaL ad in&od
Twnour model
A total of 15 mixed sex Wistar rats with mean body weight
of 290.0 g (45.9 g s.d.) were randomly assigned to three equal
groups for the purposes of the study. The tumour cell line
used was derived from DMH-induced colonic carcinomas
and was delivered on tumour spheroids usng the method of
Archer and Gray (1988). Briefly, the model entails harvesting
tumour cells which adhere in a monolayer to ion exchange
spheroids of 32-45pm diameter. The spheroids with their
load of tumour cells can then be injected into the portal vein,
where they travel into the liver and embolise portal vessels.
Tumour deposits will then grow at the site of embolisation
and do not move into the venous system, thus confining the
seeded tumour to the liver. Growth rates and a detailed
methodology have been described previously (Archer and
Gray, 1988).
Radioactive microspheres
The radioactive microspheres used in the study were closely
sized resin-based particles of 32.5 ± 2.5sum diameter contain-
ing the highly energetic isotope yttrium-90. The isotope is a
pure beta emitter with a half life of 64h, a maximum range
in tissue of 11 mm and a mean range of 4.5 mm (KIemp et
al., 1989). The microspheres have a specific gravity of <2.0
and have been shown not to leach activity in vio, and the
partcles distribute evenly throughout the liver when
delivered intravascularly. The micrres are stable and
cause minimal tisse reaction even after being in the lver for
extensive periods (Gray et al., 1990). The activity of the
microspheres was approximately 65 Bq per sphere and a
stock suspension was dispensed at a concentration of
50 MBq perml of disilled water.
The radiation dose to liver tissue was based initially on an
estimated average liver weight of 15 g for each animal treat-
ed. Absorbed dose for tissue was caculated as 1.82 Gy for
every 37 MBq perkg of liver (Mantravadi et al., 1982). The
calculation was thus derived from the following equation:
Activity (MBq) = [dose (Gy) x weight (g) x 0.037]/1.82
The calculation however, is based on homogeneous distri-
bution of dose throughout the tissue substance. This is not
the case with point sourced radiation as provided on micro-
spheres distributed primarily in the tumour and hver vas-
culature. There will be areas of extremely high dose near the
microspheres and of low dose away from them. The mean
doses described in the calculation are thus overstated by a
constant fraction related to the tissue volume not riving
the maximum doses and doses are therefore designated as
'inferred' doses. This concept has been described in detail
previously (Fox et al., 1991), but basically means that
approximately 86% of the normal tissue receives less than
the dose that would be expected with perfectly uniform distri-
bution, and 34% of the tissue receives less than one-third of
that dose.
Protocol
A laparotomy was performed under general anaesthetic (Pen-
tabarbital, 60 mgkg-') on each animal and the portal vein
cleared distally to the liver. A total of 4 x 10' tumour
spheroids were then injected directly into the portal vein in a
volume of 0.5 ml of saline carrier. The animals were
recovered and resultant tumours allowed to grow in the liver
at the sites of random spheroid emboisation. After a further
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2 days when the tumours were still less than 1 mm in
diameter, the animals were again injected intraportally with
one of the following three treatments, assigned at ran-
dom:
1. Approximately 3.0 x 105 radioactive microspheres car-
rying a total activity of 20 MBq of 'Y. In a 15 g lver
this will equate to an inferred tissue dose of approx-
imately 66 Gy.
2. Approximately 1.5 x 10' radioactive microspheres car-
rying a total activity of 10 MBq of'Y. In a 15 g liver
this will equate to an inferred tssue dose of approx-
imately 33 Gy.
3. Approximately 3.0 x 10' non-radioactive microspheres,
equivalent to the number of microspheres in the high-
dose group.
Animal body weights were measured periodically through-
out the period from treament to eventual sacrifice. On day
21 post tumour deposition each animal received a barbiturate
overdose and the liver was removed and fixed in 10%
phosphate-buffered formalin. At that time a 1.0ml blood
sample was also taken for examination of standard lver
function tests. Venous blood samples were also taken from
an extra group offive rats without tumour seeded to the liver
as a control for the liver function tests in the animals from
the treatment groups. Folowing liver fixation the lobes were
separated and sectioned into thin slice (approximately
3 mm) for examination of the presece of tumour deposits.
Tumours were numbered individually and those associated
with each lobe combined and weighed.
Res
All animals tolerated the microsphere treatments without
difficulty and post-operative recovery, incxluding activity pat-
terns and general condition, did not vary significantly
between the groups. Tlere was, however, a small drop (less
than 5%) in body weight in the group receiving 20 MBq of
"'Y microheres im iately following treatment which was
resolved within 12 days. This may have been reLaed to the
larger radiation dose sinc neither the sham-treated animal
nor those tra with 10 MBq exhibited this reonse. The
latter animals all increased and mamintined mean body
weight following the operation (Figure 1).
At the time of sacrifice there was no obvious damag to
the liver of treated animas that could be associatd with the
radioactive m. The hvers of the animals treated
with the non-radioactive mcopes demstaed exten-
e signs of tumour deposition but otherwise there was no
damage to the normal liver parechyma. One animal in the
10 MBq group had a small number of tumour deposits sit-
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Fgwe 1 Changes in body weight ofrats treated with a high (O)
and a lw (U) dose of Y mi aoshes and a sham-treated
group (0) reciving non-radiactive m hers injetd into
the portal vein. Means are presented with standard error
bars.p drm-
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uated at the site of tumour spheroid injection in the region of
the portal vein, indicating spillage of tumour at the time of
tumour implantation.
The mean weight of residual normal liver tissue at sacrifice
for the sham-treated group and groups treated with 10 MBq
and 20 MBq was 10.38 g (2.07 g s.d.), 11.52 g (1.72 g s.d.)
and 12.87 g (1.78 g s.d.) respectively. Using the measured
weights of the treated livers with the tumour weights sub-
tracted, this calculates to an inferred liver dose delivered to
the animals of approximately 42.3 Gy and 76.4Gy for the
low and high radiation doses.
Table I describes the extent of tumour deposition resulting
from portal venous seeding of the tumour spheroids in the
different treatment groups. The sham-treated animls grew
large numbers of tumours in each liver lobe. A mean of 34
(11 s.d.) tumours were taken from each animal with a total
mass of 29.2 g for the group. A single animal with a single
tumour was recorded in the 10 MBq group, while two
animals with a total of eight tumours were found in the
group treated with 20 MBq. No clear pattern of distribution
was determined for the deposition of tumours in any of the
groups.
The mean tumour weight in the sham-treated animals was
0.16g (0.08g s.d.), while the mean tumour weight in the
radioactive microsphere-treated animals was 0.01 g and
0.05 g respectively for the 10 MBq and 20 MBq groups.
liver function tests were carried out on all animals and the
means and standard devations of each test are described in
Table H. There were no significant differences between any of
the groups in relation to either bilirubin, albumin or protein
levels in the serum. Staisical signifi was tested by
one-way ANOVA foilowed by Bonferroni correction. Aspar-
tate aminotransferase levels did not show any significant
difference in any group compared with control animals, but
the sham group demonstrated significantly higher levels
(P<0.05) than the group treated with 20 MBq. Serm
alkaline phosphatase levels were significantly inrsed
(P<0.05) in both radiation-treated groups compared with
controls but not in the sham group compared with controls.
This was reflected in the significant increases in these levels
for the radiation-treated groups compared with sham-treated
controls.
These experiments were designed to simulate in an animal
model the clinical scenario of patients with microscopic liver
metastases. This is a common event in clinical practice when
patients undergo surgical removal of a primary tumour of
the gastrointestinal tract but do not apparently have any
clinically detectable metastatic disa in their liver. However,
the fact that many of these patents do subsequently develop
overt liver metastases indicates that microscopic liver metas-
tases were present at the time of the initial surgery. This
phenomenon has underscored the rationale for using portal
venous chemotherapy as an adjuvant therapy for patients
with stage B and C large bowel cancer undergoing resection
of the primary tumour. The results of clinical trials in this
patient group have now shown that the use of adjuvant
chemotherapy given via the portal vein can result in a
significnt survival advantage for the patients having this
additional form of treatment (Taylor et al., 1985; Gray et al.,
1987; Wolmark et al., 1990).
TAe I Number and weight of seeded tumour deposits forming in different
lobes of the rats' liver after treatment with two doses of"Y m s and
sham-treed anihm with non-radioactive mohes
Left medial Right medial Left lateral Other lobes
Treamen No. Wt No. Wt No. Wt No. Wt
Shipn (total of 172 htmwurs weihtig 29.2g)
I - - 5 1.01 4 1.75 20 4.15
2 1 0.03 3 0.59 1 0.03 10 0.66
3 11 2.47 14 4.01 15 4.72 4 0.65
4 - - 1 0.16 17 1.55 24 1.85
5 8 0.79 7 1.00 10 1.68 17 2.14
10 MBq (total of oine £onor weighin 0.01 g)
I
2 - - - _ _ _ _ _
3 - - - _ _ _ _ _
4 1 0.01 - - - - - -
5 - - - _ _ _ _ _
20 Mbq (total of eight tumours weighig 0.57g)
I - - - - - - 6 0.56
2 - - - _ _ _ _ _
3 - - - - - - 2 0.01
4 - - - _ _ _ _ _
5 - - - _ _
TAe II Changes in standard liver functo tess of utreated rats
non-radioactive and ra m hes
with animal treated with
Bilrubin ADbai Protein AST Aalne phoshates
(Pnolml ') (gr' (,r (U 1) (UlI-')
Control I - 32.3 3.5 53.7 4.9 125.0 99.9 207.0 50.1
Sham 1 - 33.6 1.7 56.4 3.3 203.2 34.8 258.2 18.9
NS NS NS NS NS
10 MBq 1 - 35.3 0.5 58.8 1.7 154.3 33.9 341.3 31.5
NS NS, NS NS, NS NS, NS *, t
20MBq 1 - 35.0 1.3 58.2 1.1 140.0 43.3 327.6 37.0
NS NS, NS NS, NS NS, t *f t
Data are d as means followed by standard deviionL Sign'-anc is given below the means for
comparion of controls with the treated groups shown first (*P<0.05) and shams cmpared with radiation
tratments second (tP<0.05). In no c was a sigifiant difree between the high and low
radiation treatmts (NS = P>0.05).Adj iWen radWi thrapy
MA Burton and BN Gray x
325
Although portal venous chemotherapy is only effective in
treating very small micrometastases, radiation treatment
using the SIR therapy technique but also delivered via the
portal vein, as opposed to the hepatic artery, should
theoretically have much greater potential to destroy small
metastatic deposits by virtue of the fact that the effective
penetration distance of yttrium-90 beta-radiation is of the
order of 3 mm (Klemp et al.. 1989). Adjuvant SIR therapy
should be able to destroy micrometastases up to several
millimetres in diameter as it does not rely on diffusion of
drug from a nearby portal venous radicle.
The results of these animal experiments clearly show that
the administration of a single dose of yttrium-90 can greatly
inhibit the clinical development of liver metastases in animals
that are harbounrng large numbers of microscopic metastases.
This has major potential implications for the treatment of
patients who are known at the time of treatment of the
primary tumour to have a high probability of having micro-
scopic tumour deposits within their liver.
The small deposits of tumour that did grow in three of the
ten animals treated with radiation probably resulted from
slight inhomogeneity of distribution of the microspheres from
lobe to lobe. This may lead to areas of liver that are
insufficiently irradiated to suppress the metastases and is a
common occurrence in the multilobulate liver of the rat.
Studies from this laboratory using sheep liver as an organ
model (Burton et al.. 1988) have shown that this does not
occur to the same extent where the liver is bilobular as in the
human and distribution is relatively homogeneous. We have
also experienced severe inhomogeneity when ceramic micro-
spheres are used rather than the SIR spheres. This is attri-
buted to the high specific density of ceramic microspheres,
causing sedimentation in the vasculature. and thus making
them unsuitable for clinical use.
The post-treatment liver function tests demonstrate abnor-
malities of liver enzyme function that are consistent with
some damage to the normal liver parenchyma. However,
these tests were performed on the 19th day following treat-
ment and do not reflect alterations to long-term function of
the liver that has been subjected to irradiation by yttrium-90.
In patients with established liver metastases we have shown
that it is possible to deliver inferred liver radiation doses of
the order of 74 Gy without any obvious long-term sequelae
(Gray et al., 1990), and more recently patients are routinely
receiving inferred doses of up to 92 Gy again without
measureable toxicity. Furthermore. as both the low (42 Gy)
and high (76 Gy) radiation doses used in these animal
experiments gave similar results, it may be possible to use
even lower doses to produce this same result.
On theoretical grounds. it would seem more appropriate to
use adjuvant SIR therapy via the hepatic arterial supply,
rather than via the portal vein. While this is true, the realities
of surgical practice are that it is technically much easier to
cannulate a vein in the portal circulation than the hepatic
artery. If adjuvant SIR therapy is to be accepted as a clinical
modality, the ease of use by the general surgical community
is a major factor to be considered. In addition, it must be
ensured that radioactive microspheres do not pass through
the liver and enter the pulmonary circulation. Where radioac-
tive microspheres are currently used clinically, a pretreatment
procedure involves assessment of lung uptake of activity by
analysis of distribution of injected 9Tc-labelled macroaggre-
gated albumin particles of similar size to microspheres. If
excessive activity is breaking through the liver to the lung
then the treatment is not continued. A similar procedure
would need to be employed in the adjuvant setting.
The use of SIR therapy should now be evaluated as an
adjuvant treatment for patients at high risk of developing
liver metastases.
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